Pyxis Oncology, Inc. (PYXS): Revenue

Annual figures by period end, from SEC filings.

$13.86M

Year ended 2025-12-31

2024-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$13.86M	-14.2%	2026-03-23, From 2025-01-01
2024-12-31	$16.15M	n/a	2026-03-23, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Pyxis Oncology, Inc. (PYXS)	2025-12-31	$13.86M	-14.2%
CV Sciences, Inc. (CVSI)	2025-12-31	$13.79M	-12.2%
Arbutus Biopharma Corp (ABUS)	2025-12-31	$14.08M	+128.2%
Opus Genetics, Inc. (IRD)	2025-12-31	$14.20M	+29.1%
Palatin Technologies Inc (PTN)	2026-06-30	$13.19M	n/a
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	$13.11M	+29.8%
Evommune, Inc. (EVMN)	2025-12-31	$13.00M	+85.7%
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$12.45M	-25.2%
Prelude Therapeutics Inc (PRLD)	2025-12-31	$12.14M	+73.4%

Compare PYXS, CVSI, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗